Central European Journal of Medicine

, Volume 6, Issue 1, pp 26–30 | Cite as

LABA in patients with stage I COPD and mild sleep apnea syndrome: a pilot study

  • Ivan Kopitovic
  • Marija Kojicic
  • Mirjana Jovancevic Drvenica
  • Miroslav Ilic
Research Article


Patients suffering from both sleep apnea-hypopnea syndrome (SAHS) and chronic obstructive pulmonary disease (COPD) have a more severe form of sleep apnea. Knowing all pathophysiological aspects that mutually interact in sleep disorders and COPD, we aimed to investigate if the introduction of long-acting β2 agonists (LABA) during the night could improve overnight oxygenation and the ability to perform daily activities in stage I COPD patients with mild SAHS. We conducted a prospective study of 22 patients with stage I COPD and SAHS confirmed by overnight polygraph screening, without nocturnal CPAP treatment. During twelve weeks, all patients used LABA (salmeterol 50 mcg) with a metered dose inhaler before bedtime. The levels of apnea hypopnea index, oxygen saturation, heart rate, and Epworth daytime sleepiness scale (ESS) were recorded before and after the treatment. There was a significant improvement of lowest and average overnight oxygenation compared to baseline (mean difference 2.1±0.42, p<0.0001; 1.7±0.3, p<0.0001, respectively). In addition, patients reported reduction in daytime sleepiness according to ESS (mean difference 1.23±0.51; p=0.03). Fewer patients exhibited tachycardia when on salmeterol (68 vs. 41%; p=0.01). Use of inhaled salmeterol improves overnight oxygenation in patients with stage I COPD and SAHS. Future prospective studies are warranted to confirm this potentially beneficial effect of long-acting β2 agonists.


COPD Night hypoxemia Sleep apnea Adrenergic beta-agonists Polygraphy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001: 163(5): 1256–1276PubMedGoogle Scholar
  2. [2]
    Lindberg E, Elmasry A, Gislason T, Janson C, Bengtsson H, Hetta J, Nettelbladt M, Boman G. Evolution of sleep apnea syndrome in sleepy snorers: a population-based prospective study. Am J Respir Crit Care Med 1999: 159(6): 2024–2027PubMedGoogle Scholar
  3. [3]
    McNicholas WT. Impact of sleep in COPD. Chest 2000: 117(2 Suppl): 48S–53SCrossRefPubMedGoogle Scholar
  4. [4]
    Weitzenblum E, Chaouat A, Kessler R, Canuet M. Overlap syndrome: obstructive sleep apnea in patients with chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008: 5(2):237–241CrossRefPubMedGoogle Scholar
  5. [5]
    Jelic S. Diagnostic and therapeutic approach to coexistent chronic obstructive pulmonary disease and obstructive sleep apnea. Int J Chron Obstruct Pulmon Dis 2008: 3(2): 269–275PubMedGoogle Scholar
  6. [6]
    Bradley TD, Rutherford R, Grossman RF, Lue F, Zamel N, Moldofsky H, Phillipson EA. Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome. Am Rev Respir Dis 1985: 131(6): 835–839PubMedGoogle Scholar
  7. [7]
    Chaouat A, Weitzenblum E, Krieger J, Ifoundza T, Oswald M, Kessler R. Association of chronic obstructive pulmonary disease and sleep apnea syndrome. Am J Respir Crit Care Med 1995: 151(1): 82–86PubMedGoogle Scholar
  8. [8]
    Lavie P, Herer P, Peled R, Berger I, Yoffe N, Zomer J, Rubin AH. Mortality in sleep apnea patients: a multivariate analysis of risk factors. Sleep 1995: 18(3): 149–157PubMedGoogle Scholar
  9. [9]
    Hiestand D, Phillips B. The overlap syndrome: chronic obstructive pulmonary disease and obstructive sleep apnea. Crit Care Clin 2008: 24(3): 551–563, viiCrossRefPubMedGoogle Scholar
  10. [10]
    McNicholas WT. COPD and Obstructive Sleep apnea: Overlaps in Pathophysiology, Systemic Inflammation and Cardiovascular Disease. Am J Respir Crit Care Med 2009Google Scholar
  11. [11]
    Martin RJ, Cicutto LC, Smith HR, Ballard RD, Szefler SJ. Airways inflammation in nocturnal asthma. Am Rev Respir Dis 1991: 143(2): 351–357PubMedGoogle Scholar
  12. [12]
    Martin RJ. Small airway and alveolar tissue changes in nocturnal asthma. Am J Respir Crit Care Med 1998: 157(5 Pt 2): S188–190PubMedGoogle Scholar
  13. [13]
    Wiegand L, Mende CN, Zaidel G, Zwillich CW, Petrocella VJ, Yancey SW, Rickard KA. Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma. Chest 1999: 115(6): 1525–1532CrossRefPubMedGoogle Scholar
  14. [14]
    Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999: 22(5): 667–689Google Scholar
  15. [15]
    Sanders MH, Newman AB, Haggerty CL, Redline S, Lebowitz M, Samet J, O’Connor GT, Punjabi NM, Shahar E. Sleep and sleep-disordered breathing in adults with predominantly mild obstructive airway disease. Am J Respir Crit Care Med 2003: 167(1): 7–14CrossRefPubMedGoogle Scholar
  16. [16]
    Shaya FT, Lin PJ, Aljawadi MH, Scharf SM. Elevated economic burden in obstructive lung disease patients with concomitant sleep apnea syndrome. Sleep Breath 2009Google Scholar
  17. [17]
    Engleman HM, Kingshott RN, Wraith PK, Mackay TW, Deary IJ, Douglas NJ. Randomized placebo-controlled crossover trial of continuous positive airway pressure for mild sleep Apnea/Hypopnea syndrome. Am J Respir Crit Care Med 1999: 159(2): 461–467PubMedGoogle Scholar
  18. [18]
    Barnes M, Houston D, Worsnop CJ, Neill AM, Mykytyn IJ, Kay A, Trinder J, Saunders NA, Douglas McEvoy R, Pierce RJ. A randomized controlled trial of continuous positive airway pressure in mild obstructive sleep apnea. Am J Respir Crit Care Med 2002: 165(6): 773–780PubMedGoogle Scholar
  19. [19]
    Catterall JR, Calverley PM, MacNee W, Warren PM, Shapiro CM, Douglas NJ, Flenley DC. Mechanism of transient nocturnal hypoxemia in hypoxic chronic bronchitis and emphysema. J Appl Physiol 1985: 59(6): 1698–1703PubMedGoogle Scholar
  20. [20]
    Sandek K, Andersson T, Bratel T, Lagerstrand L. Ventilation-perfusion inequality in nocturnal hypoxaemia due to chronic obstructive lung disease (COLD). Clin Physiol 1995: 15(5): 499–513CrossRefPubMedGoogle Scholar
  21. [21]
    Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997: 112(2): 336–340CrossRefPubMedGoogle Scholar
  22. [22]
    Barnes PJ. Effect of beta-agonists on inflammatory cells. J Allergy Clin Immunol 1999: 104(2 Pt 2): S10–17CrossRefPubMedGoogle Scholar
  23. [23]
    Maris NA, de Vos AF, Dessing MC, Spek CA, Lutter R, Jansen HM, van der Zee JS, Bresser P, van der Poll T. Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Respir Crit Care Med 2005: 172(7): 878–884CrossRefPubMedGoogle Scholar
  24. [24]
    Sabater JR, Lee TA, Abraham WM. Comparative effects of salmeterol, albuterol, and ipratropium on normal and impaired mucociliary function in sheep. Chest 2005: 128(5): 3743–3749CrossRefPubMedGoogle Scholar
  25. [25]
    Kerr HD. Diurnal variation of respiratory function independent of air quality: experience with an environmentally controlled exposure chamber for human subjects. Arch Environ Health 1973: 26(3): 144–152PubMedGoogle Scholar
  26. [26]
    Fitzpatrick MF, Mackay T, Driver H, Douglas NJ. Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist. BMJ 1990: 301(6765): 1365–1368CrossRefPubMedGoogle Scholar
  27. [27]
    Rasche K, Duchna HW, Lauer J, Orth M, Kotterba S, Bauer TT, Gillissen A, Schultze-Werninghaus G. Obstructive Sleep Apnea and Hypopnea Efficacy and Safety of a Long-Acting beta2-Agonist. Sleep Breath 1999: 3(4): 125–130CrossRefPubMedGoogle Scholar

Copyright information

© © Versita Warsaw and Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Ivan Kopitovic
    • 1
  • Marija Kojicic
    • 1
  • Mirjana Jovancevic Drvenica
    • 1
  • Miroslav Ilic
    • 1
  1. 1.Institute for Pulmonary Diseases of VojvodinaSremska KamenicaSerbia

Personalised recommendations